Richard Nolan Townsend, Chief Executive Officer at Lexeo Therapeutics, Inc. (LXEO), sold 109,900 shares at $16.45 ($1.8M) on 2024-07-10, disclosed to the SEC on 2024-07-12.
Scheduled sale ($1.8M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.45 | 23,622 | $389K | 21.1% |
| 2 | $16.45 | 23,622 | $389K | 21.1% |
| 3 | $16.85 | 3,347 | $56K | 3.1% |
| 4 | $16.85 | 3,347 | $56K | 3.1% |
| 5 | $17.06 | 27,931 | $477K | 25.8% |
| 6 | $17.06 | 27,931 |
| $477K |
| 25.8% |
| 7 | $19.06 | 100 | $2K | 0.1% |
| Total | $16.79 avg | 109,900 | $1.8M | 100% |
| Filing → |
| LXEO | SELL | 2026-05-20 | $17K | — | Filing → |
| LXEO | SELL | 2026-04-07 | $313K | — | Filing → |
| LXEO | SELL | 2026-02-20 | $65K | — | Filing → |